NDA 205919 · Nova Labs LTD
Purixan
Mercaptopurine · Oral
OrphanLast checked: Nov 20, 2026Latest source record: Jul 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Apr 28, 2014
Approved uses
1
Original approval plus efficacy supplements
Registered trials
396
144 Phase 3, 58 recruiting
FAERS reports
18,153
15,651 serious, 1,997 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 20, 2026.
MERCAPTOPURINE is a nucleoside metabolic inhibitor indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen. ( 1.1 ) 1.1 Acute Lymphoblastic Leukemia MERCAPTOPURINE is indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.
Mechanism: Mercaptopurine is a purine analog that undergoes intracellular transport and activation to form metabolites including thioguanine nucleotides (TGNs). Incorporation of TGNs into DNA or RNA results in cell-cycle arrest and cell death. TGNs and other mercaptopurine metabolites are also inhibitors of de novo purine synthesis and purine nucleotide interconversions. Mercaptopurine was cytotoxic to proliferating cancer cells in vitro and had antitumor activity in mouse tumor models. It is not known which of the biochemical effects of mercaptopurine and its metabolites are directly or predominantly...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 28, 2014 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLabelLetterReview
1 products under this application
- PURIXAN · MERCAPTOPURINE 20MG/ML · SUSPENSION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Mercaptopurine" as an intervention, any sponsor and status, largest first.
- Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic LymphomaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT01190930 · 9,350 participants · Start Aug 11, 2010 · Primary completion Mar 31, 2019
Drug: Cyclophosphamide; Cytarabine and 8 more · For: Acute Lymphoblastic Leukemia; Adult B Lymphoblastic Lymphoma; Ann Arbor Stage I B Lymphoblastic Lymphoma and 7 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 243 sites in all
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03914625 · 6,720 participants (planned) · Start Jul 3, 2019 · Primary completion Sep 30, 2027
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 13 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 228 sites in all
- International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
University Hospital Schleswig-HolsteinAcademic, hospital or other
NCT01117441 · 6,136 participants · Start Jun 2010 · Primary completion Dec 31, 2021
Drug: PEG-L-asparaginase; cyclophosphamide and 14 more · For: Leukemia
Sites: Randwick, Australia; Westmead, Australia; Dornbirn, Austria · 139 sites in all
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03959085 · 5,951 participants (planned) · Start Oct 31, 2019 · Primary completion Mar 31, 2032
Drug: Blinatumomab; Calaspargase Pegol and 14 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 231 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02883049 · 5,949 participants · Start Feb 29, 2012 · Primary completion Dec 31, 2022
Drug: Clofarabine; Cyclophosphamide and 14 more · For: B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, BCR-ABL1-Like; Central Nervous System Leukemia and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 239 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00103285 · 5,377 participants · Start Apr 11, 2005 · Primary completion Dec 30, 2013
Drug: Cyclophosphamide; Cytarabine and 8 more · For: Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia
Sites: Birmingham, Alabama; Mobile, Alabama; Mesa, Arizona · 236 sites in all
- Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017Pivotal-lookingRecruiting
Martin SchrappeAcademic, hospital or other
NCT03643276 · 5,000 participants (planned) · Start Jul 15, 2018 · Primary completion Jul 14, 2028
Drug: Blinatumomab; Bortezomib and 17 more · For: Acute Lymphoblastic Leukemia, Pediatric
Sites: Sydney, Australia; Westmead, Australia; Graz, Austria · 115 sites in all
- Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
University Hospital Schleswig-HolsteinAcademic, hospital or other
NCT00430118 · 4,559 participants · Start Jul 2000 · Primary completion Jan 2012
Drug: asparaginase; cyclophosphamide and 12 more · For: Leukemia
Sites: Dornbirn, Austria; Feldkirch-Tisis, Austria; Graz, Austria · 76 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- febrile neutropenia1,952
- off label use1,399
- pyrexia1,229
- drug ineffective1,122
- nausea825
- vomiting796
- abdominal pain724
- diarrhoea721
- neutropenia627
- headache614
- fatigue567
- pneumonia541
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 192 |
| 2005 | 151 |
| 2006 | 163 |
| 2007 | 223 |
| 2008 | 272 |
| 2009 | 478 |
| 2010 | 554 |
| 2011 | 643 |
| 2012 | 830 |
| 2013 | 465 |
| 2014 | 765 |
| 2015 | 817 |
| 2016 | 928 |
| 2017 | 1,156 |
| 2018 | 1,319 |
| 2019 | 1,277 |
| 2020 | 1,187 |
| 2021 | 1,379 |
| 2022 | 1,435 |
| 2023 | 1,287 |
| 2024 | 1,190 |
| 2025 | 859 |
| 2026 | 583 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Purixan (Mercaptopurine)
2024 spending
$62K
Beneficiaries
n/a
34 claims
Per beneficiary
n/a
$14.53 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $61,435 |
| 2021 | $125,467 |
| 2022 | $116,167 |
| 2023 | $58,605 |
| 2024 | $61,734 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.
Jabbour E, Short NJ, Senapati J, et al. · Lancet Haematol 2023 · Clinical Trial, Phase II
- Crohn's disease.
Mills SC, von Roon AC, Tekkis PP, et al. · BMJ Clin Evid 2011 · Systematic Review
- Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial.
Jabbour E, Short NJ, Jain N, et al. · Lancet Haematol 2022 · Clinical Trial, Phase II
- Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian HM, O'Brien S, Smith TL, et al. · J Clin Oncol 2000 · Clinical Trial, Comparative Study
- Crohn's disease.
von Roon AC, Reese GE, Orchard TR, et al. · BMJ Clin Evid 2007 · Systematic Review
- Crohn's disease.
Mills SC, von Roon AC, Tekkis PP, et al. · BMJ Clin Evid 2010 · Systematic Review
Sponsor: Nova Labs LTD
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.